Contact Us
Drug Search Results
More Filters [+]

AL-78898A

Alternative Names: al-78898a, pot-4
Latest Update: 2024-04-15
Latest Update Note: News Article

Product Description

AL-78898A Inhibits Complement Deposition in a Primate Light Damage Model (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2359062)

Mechanisms of Action: C3 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AL-78898A

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Wet Macular Degeneration|Macular Degeneration|Geographic Atrophy

Phase 1: Wet Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
C-12-020

P2

Terminated

Macular Degeneration|Geographic Atrophy

2012-11-01

RACE

P2

Completed

Wet Macular Degeneration

2012-04-01

ASaP

P1

Completed

Wet Macular Degeneration

2010-02-01

Recent News Events

Date

Type

Title

04/15/2024

News Article

 Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024

08/01/2023

PubMed

 The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.

04/04/2023

PubMed

 In vitro evaluation of iron oxide nanoparticle-induced thromboinflammatory response using a combined human whole blood and endothelial cell model.

03/13/2023

PubMed

 Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions